Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nextcure Inc (NXTC)

Nextcure Inc (NXTC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,523
  • Shares Outstanding, K 2,680
  • Annual Sales, $ 0 K
  • Annual Income, $ -55,650 K
  • EBIT $ -60 M
  • EBITDA $ -59 M
  • 60-Month Beta 1.54
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.26

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -2.26
  • Number of Estimates 2
  • High Estimate -2.14
  • Low Estimate -2.38
  • Prior Year -4.92
  • Growth Rate Est. (year over year) +54.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.89 +28.12%
on 11/18/25
15.74 -27.64%
on 11/24/25
+2.87 (+33.69%)
since 11/11/25
3-Month
5.19 +119.44%
on 09/15/25
15.74 -27.64%
on 11/24/25
+5.95 (+109.38%)
since 09/11/25
52-Week
2.69 +323.74%
on 04/10/25
15.74 -27.64%
on 11/24/25
-2.17 (-16.00%)
since 12/11/24

Most Recent Stories

More News
NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference

BELTSVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class...

NXTC : 11.39 (-2.57%)
NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts

Extends cash runway into first half of 2027, beyond planned first half of 2026  proof of concept (“POC”) data readouts of SIM0505 (CDH6 ADC) and LNCB74 (B7-H4 ADC) Led by Ikarian Capital, Squadron...

NXTC : 11.39 (-2.57%)
NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules

BELTSVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, today announced...

NXTC : 11.39 (-2.57%)
NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results

BELTSVILLE, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) --   NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class...

NXTC : 11.39 (-2.57%)
NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States

First U.S. patient dosed at a mid-tier dose level where multiple responses have been observed Multi-regional trial to accelerate time to proof-of-concept data in 1H 2026 BELTSVILLE, Md. and SHANGHAI,...

NXTC : 11.39 (-2.57%)
NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference

BELTSVILLE, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class...

NXTC : 11.39 (-2.57%)
NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results

Announced strategic partnership with Simcere Zaiming for Phase 1 program SIM0505 (CDH6 ADC) with plans to dose the first SIM0505 patient in the United States this quarter Currently in cohort 4 of the...

NXTC : 11.39 (-2.57%)
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta

BELTSVILLE, Md., July 24, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc.  (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class...

NXTC : 11.39 (-2.57%)
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

NXTC : 11.39 (-2.57%)
NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025

NXTC : 11.39 (-2.57%)

Business Summary

NextCure Inc. is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company's product candidate consists of NC318 and NC410 which are in clinical stage. NextCure Inc. is based in Beltsville, Maryland....

See More

Key Turning Points

3rd Resistance Point 13.54
2nd Resistance Point 13.02
1st Resistance Point 12.20
Last Price 11.39
1st Support Level 10.86
2nd Support Level 10.34
3rd Support Level 9.52

See More

52-Week High 15.74
Last Price 11.39
Fibonacci 61.8% 10.75
Fibonacci 50% 9.21
Fibonacci 38.2% 7.67
52-Week Low 2.69

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar